Hepatitis C
AASLD 2016: Birth Cohort Screening and Linkage to Hepatitis C Care Still Weak in U.S.
- Details
- Category: HCV Testing & Diagnosis
- Published on Tuesday, 22 November 2016 00:00
Grave weaknesses in hepatitis C virus (HCV) screening and linkage to care are still widespread in the United States and threaten to leave a large proportion of Baby Boomers with hepatitis C untreated, according to presentations at the 2016 AASLD Liver Meeting this month in Boston.
AASLD 2016: Primary Care Providers Can Effectively Treat Patients with Hepatitis C
- Details
- Category: HCV Treatment
- Published on Tuesday, 22 November 2016 00:00
Primary care providers such as non-specialist physicians and nurse practitioners can be quickly trained to provide direct-acting antiviral (DAA) therapy for hepatitis C with a high level of treatment success and provider satisfaction, according to a presentation at the 2016 AASLD Liver Meeting this month in Boston.
AASLD 2016: AbbVie Pangenotypic Combination Cures 98% or More Across HCV Genotypes
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 November 2016 00:00
AbbVie’s combination of glecaprevir and pibrentasvir cured at least 98% of people with hepatitis C in 3 large clinical trials covering 5 out of 6 genotypes of the virus, and it is likely to receive marketing approval in the United States and European Union as the first ribavirin-free pangenotypic direct-acting antiviral combination next year, according to a report at the AASLD Liver Meeting last week in Boston.
AASLD 2016: U.S. Veterans Health System and Australia Show Potential for Rapid Hepatitis C Elimination
- Details
- Category: Approved HCV Drugs
- Published on Friday, 18 November 2016 00:00
If sufficient money is available to pay for direct-acting antivirals (DAAs), the U.S. Veterans Health Administration could cure hepatitis C in the majority of veterans under its care within 3 years, and has already shown it has the capacity to start almost 7000 people on treatment in a single month, George Ioannou of the University of Washington in Seattle reported at the AASLD Liver Meeting last week in Boston.
AASLD 2016: AbbVie Pangenotypic Combination Cures Hard-to-Treat People with HCV Genotype 3
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 November 2016 00:00
AbbVie’s pangenotypic combination of glecaprevir and pibrentasvir cured almost all of the hardest-to-treat genotype 3 hepatitis C patients -- those with cirrhosis or previous treatment experience -- in a Phase 2 trial, and looks suitable for use as an 8-week regimen for HCV genotypes 2, 4,5 and 6, according to results of studies presented at the AASLD Liver Meeting last week in Boston.
AASLD 2016: Grazoprevir Triple Regimen Demonstrates High Cure Rates, Even for Hard-to-Treat Patients
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 November 2016 00:00
A new 3-drug coformulation containing Merck's grazoprevir plus the investigational agents MK-3682 and ruzasvir was highly effective for people with hepatitis C virus (HCV) genotypes 1, 2, or 3, with sustained response rates of 86% to 100% depending on treatment duration, according to study results presented this month at the AASLD Liver Meeting in Boston. Related studies showed that the combination is also effective for retreating people who were not cured with a previous course of direct-acting antivirals (DAAs).
AASLD 2016: Grazoprevir/ Elbasvir + Sofosbuvir Highly Effective for Hard-to-Treat Genotype 3 HCV Patients
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 13 November 2016 00:00
A triple regimen of grazoprevir/elbasvir (Zepatier) plus sofosbuvir (Sovaldi) without ribavirin cured 96% of previously untreated and 97% of treatment-experienced people with hepatitis C virus (HCV) genotype 3 and liver cirrhosis, matching rates seen in easier-to-treat patient groups, according to results from the C-ISLE study presented this week at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.
AASLD 2016: 8-Week Triple Combo Cures Most Patients with Genotype 1-6 Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Thursday, 17 November 2016 00:00
A 3-drug regimen of sofosbuvir, velpatasvir, and voxilaprevir taken for 8 weeks demonstrated an overall sustained virological response rate of 95% for previously untreated patients with all hepatitis C virus (HCV) genotypes, while a 12-week regimen cured 96%-97% of people who experienced prior treatment failure on direct-acting antivirals (DAAs), according to a set of Phase 3 studies presented last week at the AASLD Liver Meeting in Boston.
AASLD 2016: Real-World Responses to HCV Treatment Among U.S. Veterans Match Best Clinical Trial Results
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 13 November 2016 00:00
Direct-acting antiviral treatment is curing people of hepatitis C in real-world clinical practice at similar rates to those seen in clinical trials, and there do not seem to be major differences between drug regimens, according to results of a large population study presented this weekend at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston.
More Articles...
- AASLD 2016: Liver Cancer Risk Reduced After Hepatitis C Treatment, But Vigilance Needed
- IDWeek 2016: New Triple DAA Combo Cures 96%-99% of People with Genotype 1-6 Hepatitis C
- HIV Glasgow: Generic Hepatitis C Drugs Purchased Online Produce High Cure Rates
- Over 1 Million People Have Been Treated with New Hepatitis Drugs, But Cost Remains a Barrier
- New Triple Combo Cures Most DAA-Experienced and Hard-to-Treat Hepatitis C Patients Without Ribavirin
Web Design and Development by